Additive pharmacological interaction between sirtuin inhibitor cambinol and paclitaxel in MCF7 luminal and MDA-MB-231 triple-negative breast cancer cells

BACKGROUND: Breast cancer (BC) is the most common malignancy and the leading cause of cancer-related death in women worldwide. Sirtuin inhibitors (SIRTi), belonging to the histone deacetylase inhibitors group (HDIs), are potent epigenetic drugs that have been investigated for therapeutic use in diff...

Descripción completa

Detalles Bibliográficos
Autores principales: Wawruszak, Anna, Okon, Estera, Telejko, Ilona, Czerwonka, Arkadiusz, Luszczki, Jarogniew
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Springer International Publishing 2022
Materias:
Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9585000/
https://www.ncbi.nlm.nih.gov/pubmed/35900723
http://dx.doi.org/10.1007/s43440-022-00393-w

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9585000/
https://www.ncbi.nlm.nih.gov/pubmed/35900723
http://dx.doi.org/10.1007/s43440-022-00393-w

Ejemplares similares